

John Buse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7048183/publications.pdf>

Version: 2024-02-01

534
papers

112,096
citations

398

133
h-index

146

327
g-index

555
all docs

555
docs citations

555
times ranked

57558
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Intensive Glucose Lowering in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 358, 2545-2559.	13.9	7,084
2	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 644-657.	13.9	5,629
3	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.	13.9	5,070
4	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	13.9	3,898
5	Follow-up Report on the Diagnosis of Diabetes Mellitus. <i>Diabetes Care</i> , 2003, 26, 3160-3167.	4.3	3,392
6	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1575-1585.	13.9	3,117
7	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
8	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. <i>Diabetes Care</i> , 2009, 32, 193-203.	4.3	2,988
9	International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. <i>Diabetes Care</i> , 2009, 32, 1327-1334.	4.3	2,651
10	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1563-1574.	13.9	2,460
11	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	4.3	2,326
12	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2018, 41, 2669-2701.	4.3	2,190
13	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	13.9	2,188
14	The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2005, 28, 2289-2304.	4.3	1,936
15	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2012, 55, 1577-1596.	2.9	1,718
16	Strategies for Multivessel Revascularization in Patients with Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2375-2384.	13.9	1,573
17	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
18	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <i>Lancet</i> , 2009, 374, 39-47.	6.3	1,324

#	ARTICLE	IF	CITATIONS
19	Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 2628-2635.	4.3	1,196
20	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet</i> , The, 2010, 376, 419-430.	6.3	1,182
21	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 233-244.	13.9	1,091
22	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2006, 29, 1963-1972.	4.3	1,089
23	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2018, 61, 2461-2498.	2.9	1,002
24	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. <i>Lancet</i> , The, 2008, 372, 1240-1250.	6.3	960
25	Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1659.	3.8	926
26	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 839-848.	13.9	903
27	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2011, 364, 818-828.	13.9	901
28	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016, 374, 1321-1331.	13.9	877
29	How Do We Define Cure of Diabetes?. <i>Diabetes Care</i> , 2009, 32, 2133-2135.	4.3	852
30	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 487-493.	4.3	846
31	Molecular Biology of Mammalian Glucose Transporters. <i>Diabetes Care</i> , 1990, 13, 198-208.	4.3	842
32	The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. <i>BMJ: British Medical Journal</i> , 2010, 340, b4909-b4909.	2.4	807
33	Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 311-320.	13.9	792
34	A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. <i>Diabetes Care</i> , 2005, 28, 1547-1554.	4.3	777
35	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). <i>Diabetes Care</i> , 2009, 32, 1224-1230.	4.3	768
36	Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1547.	3.8	718

#	ARTICLE	IF	CITATIONS
37	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , 2008, 24, 275-286.	0.9	657
38	Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8260-8265.	3.3	655
39	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium ¹²⁵ I-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015, 38, 1687-1693.	4.3	645
40	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2009, 52, 17-30.	2.9	635
41	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 114-126.	1.6	634
42	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Diabetes Care</i> , 2009, 32, 187-192.	4.3	624
43	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	2.9	598
44	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	13.9	588
45	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2007, 30, 162-172.	4.3	577
46	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. <i>Lancet</i> , The, 2010, 376, 431-439.	6.3	554
47	Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3082-3089.	1.8	528
48	Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes<subtitle>Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial</subtitle>. <i>Archives of Internal Medicine</i> , 2002, 162, 1568.	4.3	507
49	The Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 742-749.	4.3	496
50	Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. <i>American Journal of Cardiology</i> , 2007, 99, S21-S33.	0.7	491
51	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	13.9	480
52	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <i>Lancet</i> , The, 2013, 381, 117-124.	6.3	466
53	Use of Twice-Daily Exenatide in Basal Insulin ¹²⁵ I-Treated Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2011, 154, 103.	2.0	460
54	The soluble interleukin-6 receptor is generated by shedding. <i>European Journal of Immunology</i> , 1993, 23, 473-480.	1.6	458

#	ARTICLE	IF	CITATIONS
55	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <i>Lancet Neurology</i> , The, 2011, 10, 969-977.	4.9	455
56	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 105-113.	5.5	451
57	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476.	13.9	430
58	The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. <i>Science</i> , 1986, 231, 733-735.	6.0	414
59	The T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4383-4389.	1.8	392
60	Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial. <i>Diabetes Care</i> , 2010, 33, 983-990.	4.3	389
61	The metabolic syndrome: time for a critical appraisal. <i>Diabetologia</i> , 2005, 48, 1684-1699.	2.9	373
62	Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2006, 49, 1711-1721.	2.9	373
63	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Journal of the American College of Cardiology</i> , 2009, 53, 298-304.	1.2	373
64	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 221-228.	2.9	368
65	Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. <i>Diabetes Care</i> , 2013, 36, 2035-2037.	4.3	360
66	Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. <i>Nature Biomedical Engineering</i> , 2020, 4, 499-506.	11.6	353
67	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors'™ Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
68	Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. <i>Journal of Biological Chemistry</i> , 1989, 264, 7776-9.	1.6	326
69	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet</i> , The, 2012, 379, 1489-1497.	6.3	324
70	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2337-2348.	13.9	322
71	Recommendations for Management of Diabetes During Ramadan. <i>Diabetes Care</i> , 2010, 33, 1895-1902.	4.3	318
72	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Circulation</i> , 2009, 119, 351-357.	1.6	308

#	ARTICLE	IF	CITATIONS
73	DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. <i>Diabetes Care</i> , 2010, 33, 1255-1261.	4.3	308
74	A School-Based Intervention for Diabetes Risk Reduction. <i>New England Journal of Medicine</i> , 2010, 363, 443-453.	13.9	296
75	Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 885-893.	5.5	295
76	Quality of Diabetes Care in U.S. Academic Medical Centers: Low rates of medical regimen change. <i>Diabetes Care</i> , 2005, 28, 337-442.	4.3	289
77	Glucose Measurement: Confounding Issues in Setting Targets for Inpatient Management. <i>Diabetes Care</i> , 2007, 30, 403-409.	4.3	287
78	Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes. <i>Pediatrics</i> , 2015, 135, 424-434.	1.0	282
79	Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits. <i>Diabetes Care</i> , 2010, 33, 428-433.	4.3	281
80	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , 2008, 24, 275-286.	0.9	280
81	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. <i>Clinical Therapeutics</i> , 2007, 29, 139-153.	1.1	272
82	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. <i>Diabetes Care</i> , 2008, 31, 173-175.	4.3	270
83	Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement. <i>Diabetes Care</i> , 2007, 30, 2399-2400.	4.3	268
84	Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3411-3419.	1.8	258
85	H ₂ O ₂ -Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery. <i>ACS Nano</i> , 2017, 11, 613-620.	7.3	255
86	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
87	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , 2016, 39, 198-205.	4.3	240
88	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <i>Lancet</i> , 2010, 375, 1365-1374.	6.3	228
89	Recommendations for Management of Diabetes During Ramadan. <i>Diabetes Care</i> , 2005, 28, 2305-2311.	4.3	226
90	Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). <i>Diabetes Care</i> , 2014, 37, 2926-2933.	4.3	222

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1016-1027.	2.2	220
92	Hypoxia and H ₂ O ₂ Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. <i>Nano Letters</i> , 2017, 17, 733-739.	4.5	220
93	Salicylate (Salsalate) in Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2013, 159, 1.	2.0	219
94	Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2013, 36, 2254-2261.	4.3	217
95	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. <i>Diabetes Care</i> , 2014, 37, 1721-1728.	4.3	217
96	1,5-Anhydroglucitol and Postprandial Hyperglycemia as Measured by Continuous Glucose Monitoring System in Moderately Controlled Patients With Diabetes. <i>Diabetes Care</i> , 2006, 29, 1214-1219.	4.3	208
97	Effects of Rosiglitazone, Glyburide, and Metformin on β -Cell Function and Insulin Sensitivity in ADOPT. <i>Diabetes</i> , 2011, 60, 1552-1560.	0.3	208
98	Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. <i>Lancet, The</i> , 2017, 389, 369-380.	6.3	207
99	Coreâ€Shell Microneedle Gel for Self-Regulated Insulin Delivery. <i>ACS Nano</i> , 2018, 12, 2466-2473.	7.3	207
100	Effect of Alogliptin on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	3.8	206
101	Advances in transdermal insulin delivery. <i>Advanced Drug Delivery Reviews</i> , 2019, 139, 51-70.	6.6	202
102	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	3.0	196
103	A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 164-170.	2.4	194
104	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1181-1188.	4.3	194
105	Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1154-1162.	1.8	193
106	Microneedles Integrated with Pancreatic Cells and Synthetic Glucoseâ€Signal Amplifiers for Smart Insulin Delivery. <i>Advanced Materials</i> , 2016, 28, 3115-3121.	11.1	193
107	Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin A1c, and 1,5-Anhydroglucitol in Over 2000 Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1689-1694.	1.8	191
108	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S4-S20.	0.7	189

#	ARTICLE	IF	CITATIONS
109	Synthetic beta cells for fusion-mediated dynamic insulin secretion. <i>Nature Chemical Biology</i> , 2018, 14, 86-93.	3.9	184
110	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013, 166, 823-830.e5.	1.2	182
111	Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 990.	3.8	182
112	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2262.	3.8	182
113	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 898.	3.8	181
114	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. <i>JAMA Network Open</i> , 2021, 4, e2116901.	2.8	179
115	Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia. <i>Diabetes Care</i> , 2007, 30, 2458-2464.	4.3	172
116	Human intestinal glucose transporter expression and localization of GLUT5. <i>American Journal of Physiology - Cell Physiology</i> , 1992, 262, C795-C800.	2.1	171
117	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018, 41, 1970-1980.	4.3	170
118	Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. <i>American Heart Journal</i> , 2008, 155, 215-223.	1.2	168
119	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE4D). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2585-2597.	2.2	164
120	COVID-19, Hyperglycemia, and New-Onset Diabetes. <i>Diabetes Care</i> , 2021, 44, 2645-2655.	4.3	164
121	Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents. <i>Diabetes Care</i> , 2010, 33, 1300-1303.	4.3	163
122	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1693-1701.	4.3	159
123	Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 528-539.	5.5	156
124	Serum 1,5-Anhydroglucitol (GlycoMark [®]): A Short-Term Glycemic Marker. <i>Diabetes Technology and Therapeutics</i> , 2003, 5, 355-363.	2.4	154
125	Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. <i>Journal of Pediatrics</i> , 2015, 167, 627-632.e4.	0.9	150
126	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2016, 39, 701-708.	4.3	150

#	ARTICLE	IF	CITATIONS
127	Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 ⁺ T Cells in Type 1 Diabetes. <i>Science Translational Medicine</i> , 2013, 5, 191ra82.	5.8	149
128	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020, 43, 1695-1703.	4.3	147
129	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , 2019, 42, 2262-2271.	4.3	146
130	Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, S47-S47.	4.3	143
131	The Safety of Incretin-Based Therapies—Review of the Scientific Evidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2027-2031.	1.8	143
132	Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels. <i>JAMA Internal Medicine</i> , 2014, 174, 324.	2.6	142
133	Development and validation of the Diabetes Numeracy Test (DNT). <i>BMC Health Services Research</i> , 2008, 8, 96.	0.9	141
134	Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation. <i>Advanced Materials</i> , 2020, 32, e1902004.	11.1	138
135	Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes. <i>Journal of Clinical Investigation</i> , 1994, 93, 578-585.	3.9	137
136	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017, 2, 370.	3.0	136
137	The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 1067-1074.	4.3	133
138	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2532-2540.	2.2	133
139	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
140	Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , 2013, 36, 490-490.	4.3	130
141	Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin. <i>Biomacromolecules</i> , 2014, 15, 3495-3502.	2.6	130
142	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 603-610.	4.3	126
143	Red Blood Cells for Glucose-Responsive Insulin Delivery. <i>Advanced Materials</i> , 2017, 29, 1606617.	11.1	126
144	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , 2018, 61, 48-57.	2.9	126

#	ARTICLE	IF	CITATIONS
145	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1695-1702.	1.8	125
146	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , 2018, 61, 58-65.	2.9	124
147	The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 133-156.	2.2	122
148	DURABILITY of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results. <i>Diabetes Care</i> , 2009, 32, 1007-1013.	4.3	119
149	One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 965-973.	2.2	115
150	Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants. <i>Diabetes Care</i> , 2012, 35, 1008-1014.	4.3	114
151	Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings. <i>JAMA Internal Medicine</i> , 2017, 177, 920.	2.6	114
152	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2016, 39, 1186-1201.	4.3	113
153	Bioresponsive Microneedles with a Sheath Structure for H ₂ O ₂ and pH Cascade-Triggered Insulin Delivery. <i>Small</i> , 2018, 14, e1704181.	5.2	113
154	Endothelial Dysfunction: Associations with Exposure to Ambient Fine Particles in Diabetic Individuals. <i>Environmental Health Perspectives</i> , 2008, 116, 1666-1674.	2.8	110
155	Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. <i>Diabetes Care</i> , 2017, 40, 1034-1040.	4.3	104
156	Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. <i>Science Advances</i> , 2019, 5, eaaw4357.	4.7	104
157	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 46-52.	5.5	103
158	Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. <i>Diabetes Care</i> , 2011, 34, 2403-2405.	4.3	102
159	A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. <i>Pediatric Diabetes</i> , 2014, 15, 110-117.	1.2	102
160	Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 237-240.	0.9	101
161	THE ROLE OF THE HUMAN PLACENTA IN THE TRANSFER AND METABOLISM OF INSULIN*. <i>Journal of Clinical Investigation</i> , 1962, 41, 29-41.	3.9	97
162	Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2007, 51, 8-11.	2.9	96

#	ARTICLE	IF	CITATIONS
163	Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: A Cross-Sectional Study in Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , 2016, 124, 104-111.	2.8	96
164	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , 2016, 59, 1645-1654.	2.9	95
165	Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses.. <i>Journal of Experimental Medicine</i> , 1984, 159, 1629-1636.	4.2	93
166	Muraglitazar, a dual (α/β) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. <i>Clinical Therapeutics</i> , 2005, 27, 1181-1195.	1.1	93
167	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.	4.3	92
168	Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN) Trial. <i>Diabetes Care</i> , 2017, 40, 1000-1007.	4.0	90
169	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
170	Troglitazone Use in Insulin-Treated Type 2 Diabetic Patients. <i>Diabetes Care</i> , 1998, 21, 1455-1461.	4.3	86
171	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 42-54.	2.2	85
172	Inpatient Transition to Virtual Care During COVID-19 Pandemic. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 444-448.	2.4	85
173	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. <i>American Heart Journal</i> , 2008, 156, 623-632.	1.2	84
174	Pioglitazone Therapy in Patients With Stroke and Prediabetes. <i>JAMA Neurology</i> , 2019, 76, 526.	4.5	83
175	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	1.2	82
176	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018, 138, 2884-2894.	1.6	82
177	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. <i>Diabetes Care</i> , 2018, 41, 1783-1791.	4.3	82
178	Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus.. <i>Journal of Clinical Investigation</i> , 1991, 88, 1323-1330.	3.9	82
179	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.	1.6	80
180	Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. <i>Particle and Fibre Toxicology</i> , 2010, 7, 14.	2.8	79

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 563-574.	5.5	79
182	We Can Change the Natural History of Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2668-2676.	4.3	75
183	Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1877-1881.	1.2	74
184	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 82-91.	2.2	74
185	Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. <i>Diabetes Care</i> , 2016, 39, 92-100.	4.3	74
186	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , 2018, 41, 2229-2235.	4.3	74
187	Exploring salivary proteomes in edentulous patients with type 2 diabetes. <i>Molecular BioSystems</i> , 2012, 8, 1304.	2.9	73
188	Health-Related Quality of Life and Treatment Satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) Trial. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 143-151.	2.4	73
189	COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. <i>Diabetes Care</i> , 2020, 43, 1378-1381.	4.3	71
190	Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 571-575.	2.4	68
191	5. Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, S44-S47.	4.3	67
192	The GENNID Study: A resource for mapping the genes that cause NIDDM. <i>Diabetes Care</i> , 1996, 19, 864-872.	4.3	65
193	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1797-1799.	13.9	65
194	Dual self-regulated delivery of insulin and glucagon by a hybrid patch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29512-29517.	3.3	64
195	HEALTHY study rationale, design and methods: moderating risk of type 2 diabetes in multi-ethnic middle school students. <i>International Journal of Obesity</i> , 2009, 33, S4-S20.	1.6	63
196	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2017, 40, 966-972.	4.3	63
197	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
198	Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 955-958.	4.3	62

#	ARTICLE	IF	CITATIONS
199	Glucose-responsive oral insulin delivery for postprandial glyceimic regulation. Nano Research, 2019, 12, 1539-1545.	5.8	61
200	Dipeptidylâ€peptidaseâ€4 inhibitors and pancreatic cancer: a cohort study. Diabetes, Obesity and Metabolism, 2014, 16, 1247-1256.	2.2	60
201	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care, 2017, 40, 1763-1770.	4.3	60
202	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603.	4.3	59
203	Diabetes Screening With Hemoglobin A1c Versus Fasting Plasma Glucose in a Multiethnic Middle-School Cohort. Diabetes Care, 2013, 36, 429-435.	4.3	58
204	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care, 2014, 37, 2647-2659.	4.3	58
205	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) Tj ETQq1 1 0.784314 rgBT /Overl Journal, 2016, 179, 175-183.	1.2	58
206	Rationale, design and methods for process evaluation in the HEALTHY study. International Journal of Obesity, 2009, 33, S60-S67.	1.6	57
207	Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. Molecular BioSystems, 2013, 9, 2785.	2.9	57
208	The effects of the HEALTHY study intervention on middle school student dietary intakes. International Journal of Behavioral Nutrition and Physical Activity, 2011, 8, 7.	2.0	56
209	Human GLUT4/Muscle-Fat Glucose-Transporter Gene: Characterization and Genetic Variation. Diabetes, 1992, 41, 1436-1445.	0.3	55
210	Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes/Metabolism Research and Reviews, 2009, 25, 558-565.	1.7	55
211	Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. Diabetes, Obesity and Metabolism, 2019, 21, 2203-2210.	2.2	55
212	Combining insulin and oral agents. American Journal of Medicine, 2000, 108, 23-32.	0.6	54
213	Rationale, design and methods of the HEALTHY study nutrition intervention component. International Journal of Obesity, 2009, 33, S29-S36.	1.6	54
214	Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia, 2012, 55, 1641-1650.	2.9	54
215	LEADER 3â€Lipase and Amylase Activity in Subjects With Type 2 Diabetes. Pancreas, 2014, 43, 1223-1231.	0.5	54
216	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the <sc>DEVOTE</sc>, <sc>LEADER</sc> and <sc>SUSTAIN</sc>â€6 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2020, 22, 1537-1547.	2.2	54

#	ARTICLE	IF	CITATIONS
217	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1128-1141.	1.2	53
218	Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 78-86.	2.2	52
219	A survey of practices for the use of electronic health records to support research recruitment. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 246-252.	0.3	51
220	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2018, 41, 1663-1671.	4.3	51
221	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019, 42, 919-930.	4.3	51
222	The insulin resistance syndrome and coronary artery disease. <i>Coronary Artery Disease</i> , 2003, 14, 335-348.	0.3	50
223	Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes. <i>JAMA Ophthalmology</i> , 2010, 128, 312.	2.6	50
224	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
225	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	4.3	49
226	Social marketing-based communications to integrate and support the HEALTHY study intervention. <i>International Journal of Obesity</i> , 2009, 33, S52-S59.	1.6	48
227	Associations between Arsenic Species in Exfoliated Urothelial Cells and Prevalence of Diabetes among Residents of Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , 2014, 122, 1088-1094.	2.8	48
228	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138.	2.7	48
229	Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. <i>Journal of Biological Chemistry</i> , 1992, 267, 11673-6.	1.6	48
230	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1915-1924.	4.3	47
231	Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	47
232	Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. <i>Diabetes Care</i> , 2013, 36, 2162-2168.	4.3	46
233	INHIBITION OF GLUCOSE-STIMULATED INSULIN RELEASE FROM β ² TC3 CELLS AND RODENT ISLETS BY AN ANALOG OF FK506. <i>Transplantation</i> , 1993, 55, 186-191.	0.5	45
234	Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. <i>Endocrine Practice</i> , 2011, 17, 906-913.	1.1	44

#	ARTICLE	IF	CITATIONS
235	Metabolomic Characteristics of Arsenic-Associated Diabetes in a Prospective Cohort in Chihuahua, Mexico. <i>Toxicological Sciences</i> , 2015, 144, 338-346.	1.4	44
236	Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2017, 40, 1787-1789.	4.3	44
237	Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2885-2893.	2.2	44
238	Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2004, 20, 215-223.	0.9	43
239	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. <i>Diabetes Care</i> , 2021, 44, 1564-1572.	4.3	43
240	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , 2018, 67, .	0.3	42
241	40th EASD Annual Meeting of the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2004, 47, A1-A464.	2.9	41
242	Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of Type 1 Diabetes Mellitus patients. <i>Clinical Immunology</i> , 2014, 153, 156-164.	1.4	41
243	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. <i>Diabetes Care</i> , 2018, 41, 333-340.	4.3	41
244	Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. <i>Journal of Medical Virology</i> , 2021, 93, 4273-4279.	2.5	41
245	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , 2021, 44, 1595-1603.	4.3	41
246	The DURABILITY of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial. <i>Diabetes Care</i> , 2011, 34, 249-255.	4.3	40
247	Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin. <i>Diabetes Care</i> , 2013, 36, 3517-3525.	4.3	40
248	Evaluation of the dual peroxisome proliferator-activated receptor α/β agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. <i>American Heart Journal</i> , 2013, 166, 429-434.e1.	1.2	39
249	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. <i>JAMA Cardiology</i> , 2019, 4, 1214.	3.0	39
250	The trials and tribulations of determining HbA1c targets for diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 717-730.	4.3	39
251	Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10744-10748.	3.3	38
252	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	4.3	38

#	ARTICLE	IF	CITATIONS
253	Real-world evidence: the devil is in the detail. <i>Diabetologia</i> , 2020, 63, 1694-1705.	2.9	38
254	Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial. <i>Pediatric Obesity</i> , 2012, 7, 230-239.	1.4	37
255	Regional, age and sex differences in baseline characteristics of patients enrolled in the T&E valuating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 395-402.	2.2	37
256	Rationale, design and methods of the HEALTHY study behavior intervention component. <i>International Journal of Obesity</i> , 2009, 33, S44-S51.	1.6	36
257	Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia. <i>Small</i> , 2017, 13, 1603028.	5.2	36
258	Kallikrein-induced uterine contraction independent of kinin formation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1981, 78, 6154-6157.	3.3	35
259	Rationale, design and methods of the HEALTHY study physical education intervention component. <i>International Journal of Obesity</i> , 2009, 33, S37-S43.	1.6	35
260	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 1912-1920.	4.3	35
261	Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 644-647.	2.4	34
262	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2019, 170, 423.	2.0	34
263	Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, e108-e110.	4.3	34
264	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 2000-2008.	4.3	33
265	Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 40-48.	2.2	33
266	The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. <i>American Journal of Transplantation</i> , 2021, 21, 1365-1375.	2.6	33
267	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2058-2066.	2.2	33
268	Effect of Nutrition Changes on Foods Selected by Students in a Middle School-Based Diabetes Prevention Intervention Program: The HEALTHY Experience. <i>Journal of School Health</i> , 2012, 82, 82-90.	0.8	32
269	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.3	32
270	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2018, 41, 2404-2413.	4.3	32

#	ARTICLE	IF	CITATIONS
271	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1693-1702.	2.2	32
272	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. <i>Diabetes Care</i> , 2018, 41, 1998-2009.	4.3	32
273	HLA-A2-Matched Peripheral Blood Mononuclear Cells From Type 1 Diabetic Patients, but Not Nondiabetic Donors, Transfer Insulinitis to NOD-scid/Ånull/HLA-A2 Transgenic Mice Concurrent With the Expansion of Islet-Specific CD8+ T cells. <i>Diabetes</i> , 2011, 60, 1726-1733.	0.3	31
274	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2195-2198.	13.9	31
275	Effects of glucagonâ€like peptideâ€1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2487-2492.	2.2	31
276	Genetic Variants in <i>HSD17B3</i>, <i>SMAD3</i>, and <i>IPO11</i> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 712-721.	2.3	30
277	Recruitment and retention strategies and methods in the HEALTHY study. <i>International Journal of Obesity</i> , 2009, 33, S21-S28.	1.6	29
278	Patientâ€reported outcomes are superior in patients with Typeâ€2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, openâ€label study. <i>Diabetic Medicine</i> , 2011, 28, 715-723.	1.2	29
279	Sodiumâ€glucose coâ€transporterâ€2 inhibitor use and risk of lowerâ€extremity amputation: Evolving questions, evolving answers. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1223-1236.	2.2	29
280	Injectable Biodegradable Polymeric Complex for Glucose-Responsive Insulin Delivery. <i>ACS Nano</i> , 2021, 15, 4294-4304.	7.3	29
281	Lymphocyte abnormalities in the BB rat. <i>Metabolism: Clinical and Experimental</i> , 1983, 32, 83-86.	1.5	28
282	Autoimmune endocrine disease. <i>Current Opinion in Immunology</i> , 2002, 14, 760-764.	2.4	28
283	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Spectrum</i> , 2012, 25, 154-171.	0.4	28
284	<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020, 69, 771-783.	0.3	28
285	Prevalence of the Metabolic Syndrome Among a Racially/Ethnically Diverse Group of U.S. Eighth-Grade Adolescents and Associations With Fasting Insulin and Homeostasis Model Assessment of Insulin Resistance Levels. <i>Diabetes Care</i> , 2008, 31, 2020-2025.	4.3	27
286	Student public commitment in a school-based diabetes prevention project: impact on physical health and health behavior. <i>BMC Public Health</i> , 2011, 11, 711.	1.2	27
287	Rising temperatures explain past immigration of the thermophilic oak-inhabiting beetle <i>Coraeus florentinus</i> (Coleoptera: Buprestidae) in south-west Germany. <i>Biodiversity and Conservation</i> , 2013, 22, 1115-1131.	1.2	27
288	The PROTECT study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. <i>Clinical Therapeutics</i> , 1998, 20, 257-269.	1.1	26

#	ARTICLE	IF	CITATIONS
289	The metabolic syndrome. <i>Lancet</i> , The, 2005, 366, 1921-1922.	6.3	26
290	Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. <i>Journal of Human Genetics</i> , 2012, 57, 57-61.	1.1	26
291	Is insulin the most effective injectable antihyperglycaemic therapy?. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 145-151.	2.2	25
292	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , 2018, 121, 1467-1470.	0.7	25
293	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
294	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. <i>Diabetes Care</i> , 2018, 41, 1792-1800.	4.3	25
295	A Mixed-Methods, Randomized Clinical Trial to Examine Feasibility of a Mindfulness-Based Stress Management and Diabetes Risk Reduction Intervention for African Americans with Prediabetes. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-16.	0.5	25
296	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
297	Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. <i>Oncologist</i> , 2020, 25, 579-584.	1.9	25
298	Developing Insulin Delivery Devices with Glucose Responsiveness. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 31-44.	4.0	25
299	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	4.3	25
300	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. <i>Diabetes Care</i> , 2021, 44, 2729-2737.	4.3	24
301	Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. <i>Diabetes</i> , 1991, 40, 1712-1718.	0.3	24
302	Low-Density Lipoprotein Cholesterol versus Particle Number in Middle-School Children. <i>Journal of Pediatrics</i> , 2013, 163, 355-362.e2.	0.9	23
303	Knowledge, awareness, and behaviors of endocrinologists and dentists for the relationship between diabetes and periodontitis. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 428-434.	1.1	23
304	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018, 9, 2383-2392.	1.2	23
305	Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2020, 43, 398-404.	4.3	23
306	Ambient PM _{2.5} Exposure Up-regulates the Expression of Costimulatory Receptors on Circulating Monocytes in Diabetic Individuals. <i>Environmental Health Perspectives</i> , 2011, 119, 778-783.	2.8	22

#	ARTICLE	IF	CITATIONS
307	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. <i>Diabetes</i> , 2019, 68, 1649-1662.	0.3	22
308	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1745-1751.	2.2	22
309	Type 2 Diabetes Mellitus. , 2011, , 1371-1435.		22
310	Should Postprandial Glucose Be Routinely Measured and Treated to a Particular Target? No!. <i>Diabetes Care</i> , 2003, 26, 1615-1618.	4.3	21
311	IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 389-397.	1.3	21
312	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 525-532.	2.2	21
313	The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 960-968.	4.3	21
314	BMI Change, Fitness Change and Cardiometabolic Risk Factors Among 8th Grade Youth. <i>Pediatric Exercise Science</i> , 2013, 25, 52-68.	0.5	20
315	Cardiometabolic Risk Assessments by Body Mass Index<i>z</i>-Score or Waist-to-Height Ratio in a Multiethnic Sample of Sixth-Graders. <i>Journal of Obesity</i> , 2014, 2014, 1-10.	1.1	19
316	The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 874-879.	1.2	19
317	Sodium-Dependent Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions. <i>Diabetes Care</i> , 2017, 40, e65-e66.	4.3	19
318	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19
319	Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000985.	1.2	19
320	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1690-1695.	2.2	19
321	Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. <i>Diabetes</i> , 1992, 41, 1436-1445.	0.3	19
322	Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. <i>British Journal of Psychiatry</i> , 2004, 184, s94-s101.	1.7	18
323	LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the LEADER trial: effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial: preliminary observations. <i>Diabetes, Obesity and Metabolism</i> . 2015. 17. 477-486.	2.2	18
324	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , 2015, 28, 995-1009.	1.0	18

#	ARTICLE	IF	CITATIONS
325	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. <i>Metabolism: Clinical and Experimental</i> , 2019, 98, 104-111.	1.5	18
326	Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 632-639.	0.9	18
327	Evidence supports prediabetes treatment. <i>Science</i> , 2019, 364, 341-342.	6.0	18
328	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1625-1633.	2.2	18
329	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , 2020, 11, 53-70.	1.2	18
330	Association between glycosylated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the <sc>TECOS</sc> randomized clinical trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2026-2034.	2.9	18
331	Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats.. <i>Journal of Experimental Medicine</i> , 1985, 162, 444-458.	4.2	17
332	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 970-978.	2.2	17
333	Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. <i>Diabetes Care</i> , 2019, 42, e21-e23.	4.3	17
334	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac066.	0.4	17
335	Individualizing treatment targets in diabetes care. <i>Nature Reviews Endocrinology</i> , 2011, 7, 67-68.	4.3	16
336	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , 2018, 41, 348-355.	4.3	16
337	Carbohydrate Intake Prior to Oral Glucose Tolerance Testing. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab049.	0.1	16
338	Type 1 Diabetes Mellitus. , 2011, , 1436-1461.		16
339	Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001649.	1.2	16
340	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS). <i>Drugs - Real World Outcomes</i> , 2022, , 1.	0.7	16
341	Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. <i>Epidemiology</i> , 2017, 28, 446-454.	1.2	15
342	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2019, 42, 1075-1080.	4.3	15

#	ARTICLE	IF	CITATIONS
343	Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database. <i>Diabetes Care</i> , 2022, 45, 1099-1106.	4.3	15
344	Renewal of FSP1: A marker of fibrogenesis on human renal biopsies. <i>Kidney International</i> , 2005, 68, 1366-1367.	2.6	14
345	Prevention of Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Trials on the Horizon. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 221-235.	1.2	14
346	Five linkage regions each harbor multiple type 2 diabetes genes in the African American subset of the GENNID Study. <i>Journal of Human Genetics</i> , 2013, 58, 378-383.	1.1	14
347	Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 129-140.	2.2	14
348	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. <i>Diabetes Care</i> , 2020, 43, 940-947.	4.3	14
349	Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. <i>Journal of the American Heart Association</i> , 2022, 11, e022376.	1.6	14
350	North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. <i>Journal of Dental Education</i> , 2011, 75, 329-38.	0.7	14
351	A dead heat: target normal glucose levels in the intensive care unit—but with caution. <i>Diabetologia</i> , 2008, 51, 909-910.	2.9	13
352	Baseline Predictors of A1C Reduction in Adults Using Sensor-Augmented Pump Therapy or Multiple Daily Injection Therapy: The STAR 3 Experience. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 601-606.	2.4	13
353	Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1065-1069.	2.2	13
354	Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study. <i>International Journal of Obesity</i> , 2016, 40, 1157-1163.	1.6	13
355	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1013-1023.	0.8	13
356	Late-Breaking Science Abstracts From the American Heart Association's Scientific Sessions 2017 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2017. <i>Circulation</i> , 2017, 136, e448-e467.	1.6	13
357	Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution. <i>Pediatrics</i> , 2018, 142, e20181536B.	1.0	13
358	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1437-1444.	2.2	13
359	Bibliometrics approach to evaluating the research impact of CTSA: A pilot study. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 336-344.	0.3	13
360	Class I, II and III major histocompatibility complex gene polymorphisms in BB rats. <i>Diabetologia</i> , 1984, 27, 77-79.	2.9	12

#	ARTICLE	IF	CITATIONS
361	A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2007, 23, 2689-2695.	0.9	12
362	Medications for type 2 diabetes: how will we be treating patients in 50 years?. <i>Diabetologia</i> , 2015, 58, 1735-1739.	2.9	12
363	A genome-wide study of lipid response to fenofibrate in Caucasians. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 324-333.	0.7	12
364	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	1.3	12
365	Longitudinal Phenotypes of Type 1 Diabetes in Youth Based on Weight and Glycemia and Their Association With Complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6003-6016.	1.8	12
366	Causal role of frontal-midline theta in cognitive effort: a pilot study. <i>Journal of Neurophysiology</i> , 2021, 126, 1221-1233.	0.9	12
367	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, e32-e34.	4.3	12
368	Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002339.	1.2	12
369	Efficacy, safety and tolerability of alogliptazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 560-565.	2.2	11
370	Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 505-510.	2.2	11
371	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2018, 9, 1217-1232.	1.2	11
372	Identifying individual risk rare variants using protein structure guided local tests (POINT). <i>PLoS Computational Biology</i> , 2019, 15, e1006722.	1.5	11
373	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2193-2198.	2.2	11
374	Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2241-2247.	2.2	11
375	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e96.	0.3	11
376	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. <i>PeerJ</i> , 2017, 5, e3187.	0.9	11
377	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished β -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. <i>Diabetes</i> , 2022, 71, 1261-1271.	0.3	11
378	Glitazones and Heart Failure: Critical Appraisal for the Clinician. <i>Circulation</i> , 2003, 108, e57.	1.6	10

#	ARTICLE	IF	CITATIONS
379	Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONS). <i>Neurology</i> , 2009, 72, 1345-1351.	1.5	10
380	Concomitant Oral Antihyperglycemic Agent Use and Associated Treatment Outcomes After Initiation of Insulin Therapy. <i>Endocrine Practice</i> , 2011, 17, 563-567.	1.1	10
381	Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD study. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 124-130.	0.9	10
382	Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?. <i>Diabetes Care</i> , 2018, 41, 1560-1562.	4.3	10
383	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). <i>Applied Health Economics and Health Policy</i> , 2019, 17, 615-627.	1.0	10
384	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. <i>Diabetes Care</i> , 2021, 44, 1410-1418.	4.3	10
385	Clinical Experience with Continuous Glucose Monitoring in Adults. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, S-93-S-103.	2.4	9
386	The HEALTHY study: introduction. <i>International Journal of Obesity</i> , 2009, 33, S1-S2.	1.6	9
387	Univariate and Bivariate Linkage Analysis Identifies Pleiotropic Loci Underlying Lipid Levels and Type 2 Diabetes Risk. <i>Annals of Human Genetics</i> , 2010, 74, 308-315.	0.3	9
388	LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 37.	1.2	9
389	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCel Outcomes. <i>Circulation</i> , 2020, 141, 1360-1370.	1.6	9
390	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , 2020, 51, 276-288.	1.4	9
391	Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. <i>JAMA Network Open</i> , 2021, 4, e2132215.	2.8	9
392	THE USE OF INSULIN ALONE AND IN COMBINATION WITH ORAL AGENTS IN TYPE 2 DIABETES. <i>Primary Care - Clinics in Office Practice</i> , 1999, 26, 931-950.	0.7	8
393	Diabetes and periodontal therapy. <i>Journal of the American Dental Association</i> , 2014, 145, 1208-1210.	0.7	8
394	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 206-214.	2.2	8
395	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. <i>Current Medical Research and Opinion</i> , 2014, 30, 1209-1218.	0.9	8
396	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 857-866.	0.9	8

#	ARTICLE	IF	CITATIONS
397	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2450-2458.	2.2	8
398	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. <i>Diabetes Care</i> , 2019, 42, 2065-2074.	4.3	8
399	Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. <i>Pediatric Diabetes</i> , 2019, 20, 556-566.	1.2	8
400	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2248-2256.	2.2	8
401	Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00637.	1.1	8
402	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. <i>Diabetes Therapy</i> , 2021, 12, 1099-1116.	1.2	8
403	21-LB: Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial. <i>Diabetes</i> , 2020, 69, .	0.3	8
404	Screening for Diabetes and Prediabetes With Proposed A1C-Based Diagnostic Criteria. <i>Diabetes Care</i> , 2010, 33, e174-e174.	4.3	7
405	Effect of Relative Weight Group Change on Nuclear Magnetic Resonance Spectroscopy Derived Lipoprotein Particle Size and Concentrations among Adolescents. <i>Journal of Pediatrics</i> , 2014, 164, 1091-1098.e3.	0.9	7
406	CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. <i>Clinical and Translational Science</i> , 2015, 8, 623-631.	1.5	7
407	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2522-2533.	1.8	7
408	Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin. <i>Clinical Therapeutics</i> , 2019, 41, 2219-2230.e6.	1.1	7
409	Comprehensive Pulmonary Safety Review of Inhaled Technosphere [®] Insulin in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2020, 40, 973-983.	1.1	7
410	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. <i>Diabetes Care</i> , 2020, 43, 2121-2127.	4.3	7
411	100 years on: the impact of the discovery of insulin on clinical outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002373.	1.2	7
412	985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8. <i>Diabetes</i> , 2019, 68, .	0.3	7
413	Polymorphism in exon 4a of the human GLUT4/ muscle-fat facilitative glucose transporter gene detected by SSCP. <i>Nucleic Acids Research</i> , 1991, 19, 4313-4313.	6.5	6
414	Effect of Secular Trends on a Primary Prevention Trial: The HEALTHY Study Experience. <i>Childhood Obesity</i> , 2011, 7, 291-297.	0.8	6

#	ARTICLE	IF	CITATIONS
415	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. <i>Diabetes Care</i> , 2018, 41, 1196-1203.	4.3	6
416	Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting. <i>Diabetes Care</i> , 2019, 42, e89-e91.	4.3	6
417	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2096-2106.	2.2	6
418	Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase 4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 854-865.	2.2	6
419	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097093.	0.9	6
420	Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 70-77.	2.4	6
421	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 723-732.	2.3	6
422	Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin. <i>PLoS ONE</i> , 2014, 9, e109433.	1.1	6
423	Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. <i>Transactions of the American Clinical and Climatological Association</i> , 2015, 126, 62-76.	0.9	6
424	The case for a role for postprandial glucose monitoring in diabetes management. <i>Journal of Family Practice</i> , 1998, 47, S29-36.	0.2	6
425	Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 4, 37-41.	1.1	6
426	Disordered cellular immunity in type 1 diabetes of man and the BB rat. <i>Survey of Immunologic Research</i> , 1982, 1, 339-51.	0.4	6
427	Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 569-573.	1.1	5
428	Management of glycemia in type 2 diabetes. <i>Clinical Cornerstone</i> , 1998, 1, 39-57.	1.0	5
429	What We Think and What We Know. <i>Diabetes Care</i> , 2002, 25, 1876-1878.	4.3	5
430	Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. <i>Clinical Trials</i> , 2009, 6, 416-429.	0.7	5
431	Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria—a Substudy of the ACCORD Trial. <i>Clinical Chemistry</i> , 2011, 57, 341-344.	1.5	5
432	GLP-1 receptor agonists and basal insulin in type 2 diabetes. <i>Lancet</i> , The, 2014, 384, 2180-2181.	6.3	5

#	ARTICLE	IF	CITATIONS
433	Response to Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. <i>Diabetes Care</i> 2015;38:1067-1074. <i>Diabetes Care</i> , 2015, 38, e172-e173.	4.3	5
434	Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery (<i>Adv. Mater.</i> 16/2016). <i>Advanced Materials</i> , 2016, 28, 3223-3223.	11.1	5
435	Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1994-1996.	13.9	5
436	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1732-1739.	2.2	5
437	Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2018, 31, 344-347.	0.4	5
438	Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention. <i>Diabetes Care</i> , 2018, 41, 1557-1559.	4.3	5
439	Evidence for gene-smoking interactions for hearing loss and deafness in Japanese American families. <i>Hearing Research</i> , 2020, 387, 107875.	0.9	5
440	Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000886.	1.2	5
441	Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry. <i>Thyroid</i> , 2020, 30, 1397-1398.	2.4	5
442	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	1.2	5
443	Autoimmune Endocrine Disease. <i>Vitamins and Hormones</i> , 1985, 42, 253-314.	0.7	4
444	FRONTLINE: DIABETES SUPPLEMENTING EDUCATION AND QUALITY IMPROVEMENT IN FAMILY MEDICINE RESIDENCY TRAINING. <i>Annals of Family Medicine</i> , 2008, 6, 88-89.	0.9	4
445	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-43-S-55.	2.4	4
446	SAO10EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
447	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
448	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 682-690.	2.4	4
449	Characteristics and Delivery of Diabetes Shared Medical Appointments in North Carolina. <i>North Carolina Medical Journal</i> , 2019, 80, 261-268.	0.1	4
450	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 810-811.	5.5	4

#	ARTICLE	IF	CITATIONS
451	Managing the risks and benefits of clinical research in response to a pandemic. <i>Journal of Clinical and Translational Science</i> , 2021, 5, .	0.3	4
452	Applying <sc>REWIND</sc> cardiovascular disease criteria to <sc>SUSTAIN</sc> 6 and <sc>PIONEER</sc> 6: An exploratory analysis of cardiovascular outcomes with semaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1677-1680.	2.2	4
453	Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1666-1671.	2.2	4
454	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2021, 44, 2286-2292.	4.3	4
455	Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1). <i>Diabetes</i> , 2018, 67, 212-OR.	0.3	4
456	Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor. <i>Diabetes Spectrum</i> , 2021, 34, 42-51.	0.4	4
457	Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress. <i>Frontiers in Endocrinology</i> , 2021, 12, 789526.	1.5	4
458	Can We Become Victims of Our Own Success?. <i>Diabetes Care</i> , 2009, 32, 2140-2141.	4.3	3
459	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, e66-e69.	1.1	3
460	Diabetes Technology and Treatment in the Pediatric Age Group. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S-107-S-116.	2.4	3
461	Three approaches to glucose monitoring in non-insulin treated diabetes: a pragmatic randomized clinical trial protocol. <i>BMC Health Services Research</i> , 2017, 17, 369.	0.9	3
462	FP482/EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	3
463	Reasons for Increases in Complications of Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1518.	3.8	3
464	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107706.	1.2	3
465	Glucose-Responsive Systems: Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation (Adv. Mater. 13/2020). <i>Advanced Materials</i> , 2020, 32, 2070102.	11.1	3
466	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 139-140.	5.5	3
467	Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1983-1988.	2.2	3
468	Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting. <i>Journal of Clinical Medicine</i> , 2021, 10, 2878.	1.0	3

#	ARTICLE	IF	CITATIONS
469	Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients. <i>Diabetes</i> , 2018, 67, .	0.3	3
470	Implementation and Evaluation of Shared Medical Appointments for Type 2 Diabetes at a Free, Student-Run Clinic in Alamance County, North Carolina. , 2018, 2, .		3
471	Diabetes educators' knowledge, opinions and behaviors regarding periodontal disease and diabetes. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists' Association</i> , 2012, 86, 82-90.	0.1	3
472	A new class of drug in the diabetes toolbox. <i>Nature Medicine</i> , 2022, 28, 901-902.	15.2	3
473	New Insulins and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, S-39-S-46.	2.4	2
474	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. <i>Frontiers in Genetics</i> , 2016, 7, 138.	1.1	2
475	More realistic power estimation for new user, active comparator studies: an empirical example. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 462-466.	0.9	2
476	Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 666-675.	0.9	2
477	Metabolic state and gustatory perception shapes dynamic interplay between cortical excitability and motor response. <i>Brain Stimulation</i> , 2021, 14, 202-205.	0.7	2
478	Efficacy and Safety of Faster Aspart Compared with Insulin Aspart Both with Insulin Degludec in Adults with T1D. <i>Diabetes</i> , 2018, 67, 1000-P.	0.3	2
479	Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2). <i>Diabetes</i> , 2018, 67, 1179-P.	0.3	2
480	Specific class II histocompatibility gene polymorphism in BB rats. <i>Diabetes</i> , 1984, 33, 700-703.	0.3	2
481	The Role of Obsessive-Compulsive Symptoms. <i>Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , 2013, 41, 163-171.	0.4	2
482	Impact of the hepatoselective glucokinase activator <sc>TTP399</sc> on ketoacidosis during insulin withdrawal in people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1439-1447.	2.2	2
483	T-cell antigen receptor alpha chain polymorphisms in insulin-dependent diabetes. <i>Journal of Autoimmunity</i> , 1988, 1, 389-397.	3.0	1
484	Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate. <i>Diabetes Care</i> , 2003, 26, 2700-2701.	4.3	1
485	Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. <i>Cardiology Clinics</i> , 2005, 23, 211-220.	0.9	1
486	Exenatide for type 2 diabetes — Authors' reply. <i>Lancet, The</i> , 2009, 373, 122-123.	6.3	1

#	ARTICLE	IF	CITATIONS
487	Adverse events in diabetes drug trial – Authors' reply. <i>Lancet, The</i> , 2009, 374, 1144-1145.	6.3	1
488	Clinical Care Guidelines: Too Much of a Good Thing?. <i>Diabetes Care</i> , 2010, 33, 2716-2718.	4.3	1
489	Immune Intervention for Type 1 Diabetes, 2012–2013. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, S-85-S-91.	2.4	1
490	Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery. <i>Diabetes Care</i> , 2016, 39, 852-856.	4.3	1
491	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186–1201. <i>Diabetes Care</i> , 2017, 40, e23-e24.	4.3	1
492	RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL. <i>Canadian Journal of Cardiology</i> , 2017, 33, S126-S127.	0.8	1
493	Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial. <i>Canadian Journal of Diabetes</i> , 2017, 41, S5.	0.4	1
494	The War Is Not Yet Won. <i>Diabetes Care</i> , 2017, 40, 1152-1153.	4.3	1
495	Bringing closure: towards achieving a better understanding of Israel. <i>Lancet, The</i> , 2019, 394, 559.	6.3	1
496	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2040.	1.2	1
497	Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912–1920. <i>Diabetes Care</i> , 2020, 43, e30-e31.	4.3	1
498	Experimental increase of blood glucose alters resting state EEG measures of excitation–inhibition balance. <i>Experimental Physiology</i> , 2021, 106, 803-811.	0.9	1
499	Further RISE™ing to the Challenge of Type 2 Diabetes in Youth. <i>Diabetes Care</i> , 2021, 44, 1934-1937.	4.3	1
500	6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL. <i>Diabetes</i> , 2019, 68, 6-LB.	0.3	1
501	957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program. <i>Diabetes</i> , 2020, 69, 957-P.	0.3	1
502	B-vitamins influence arsenic metabolism in Mexico. <i>FASEB Journal</i> , 2013, 27, 1077.20.	0.2	1
503	Simplici-T1™ First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes. <i>Diabetes</i> , 2018, 67, 126-LB.	0.3	1
504	983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7. <i>Diabetes</i> , 2019, 68, 983-P.	0.3	1

#	ARTICLE	IF	CITATIONS
505	8-LB: Outcomes of Type 2 Diabetes (T2D) Clustering Replicated in the DEVOTE Trial. <i>Diabetes</i> , 2019, 68, .	0.3	1
506	Are Hemo-chromatosis gene mutations a risk factor for type 2 diabetes?. <i>Gastroenterology</i> , 2001, 120, A227.	0.6	0
507	Are prescribing patterns of antidiabetic medications influenced by fears of litigation?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 440-441.	2.9	0
508	Diabète et pré-diabète. , 2011, , 319-326.		0
509	Diabetes Technology and Therapy in the Pediatric Age Group. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, S-100-S-109.	2.4	0
510	New Medications for the Treatment of Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, S-119-S-133.	2.4	0
511	Drug Delivery Devices: Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia (Small) Tj ETQq1 1 0,784314 rgBT /Overl 5.2	5.2	0
512	Concerns About Conclusions of Self-monitoring of Blood Glucose—Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 1874.	2.6	0
513	LIRAGLUTIDE REDUCES CARDIOVASCULAR EVENTS AND MORTALITY IN TYPE 2 DIABETES INDEPENDENT OF LDL CHOLESTEROL AND STATIN USE: RESULTS OF THE LEADER TRIAL. <i>Canadian Journal of Cardiology</i> , 2018, 34, S123-S124.	0.8	0
514	IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN 6 CLINICAL TRIALS. <i>Canadian Journal of Cardiology</i> , 2019, 35, S147.	0.8	0
515	88 - Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: LEADER and SUSTAIN 6. <i>Canadian Journal of Diabetes</i> , 2019, 43, S32-S33.	0.4	0
516	4300 Evaluation and structure of the pilot funding program at the University of North Carolina CTSA Hub (NC TraCS). <i>Journal of Clinical and Translational Science</i> , 2020, 4, 72-72.	0.3	0
517	4299 The University of North Carolina CTSA Hub (NC TraCS) Service Evaluation: Using Customer Feedback to Improve Services. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 75-75.	0.3	0
518	A Special Thanks to the Reviewers of <i>Diabetes Care</i> . <i>Diabetes Care</i> , 2020, 43, 939-939.	4.3	0
519	Back Cover Image, Volume 93, Number 7, July 2021. <i>Journal of Medical Virology</i> , 2021, 93, ii.	2.5	0
520	The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes. <i>Yearbook of Endocrinology</i> , 2006, 2006, 40-42.	0.0	0
521	Management of Type 2 Diabetes Mellitus. , 2010, , 897-915.		0
522	Exposure to arsenic and cardiometabolic risk in Chihuahua, Mexico. <i>Arsenic in the Environment Proceedings</i> , 2014, , 526-530.	0.0	0

#	ARTICLE	IF	CITATIONS
523	Latest Developments in Continuous Glucose Monitoring, Insulin, and Adjunctive Treatments in Type 1 Diabetes. <i>US Endocrinology</i> , 2018, 14, 54.	0.3	0
524	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 56-OR.	0.3	0
525	1643-P: Prevalence of Diabetes Medication Regimens in PCORnet, the National Patient-Centered Clinical Research Network. <i>Diabetes</i> , 2019, 68, .	0.3	0
526	321-OR: A Genetic Locus on Chromosome 1p36 Associated with Cardiovascular Autonomic Neuropathy in Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	0
527	15-LB: Diabetes Duration Did Not Moderate the Reduction in Severe Hypoglycemia Seen with Degludec vs. Glargine U100 in DEVOTE. <i>Diabetes</i> , 2019, 68, .	0.3	0
528	1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes</i> , 2019, 68, 1141-P.	0.3	0
529	2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes. <i>Diabetes</i> , 2020, 69, 2160-PUB.	0.3	0
530	122-LB: The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.3	0
531	123-LB: The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose. <i>Diabetes</i> , 2020, 69, .	0.3	0
532	Treatment of postprandial hyperglycemia in type 2 diabetes. <i>Postgraduate Medicine</i> , 2001, 110, 14-9.	0.9	0
533	Panel discussion on achieving glycemic control. <i>Postgraduate Medicine</i> , 2001, 110, 20-5.	0.9	0
534	Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0